ATE498683T1 - Leptin antagonisten - Google Patents

Leptin antagonisten

Info

Publication number
ATE498683T1
ATE498683T1 AT05809259T AT05809259T ATE498683T1 AT E498683 T1 ATE498683 T1 AT E498683T1 AT 05809259 T AT05809259 T AT 05809259T AT 05809259 T AT05809259 T AT 05809259T AT E498683 T1 ATE498683 T1 AT E498683T1
Authority
AT
Austria
Prior art keywords
leptin
leptin antagonists
antagonists
amino acid
acid residues
Prior art date
Application number
AT05809259T
Other languages
English (en)
Inventor
Arieh Gertler
Isabelle Callebaut
Jean Djiane
Original Assignee
Yissum Res Dev Co
Univ Paris Curie
Agronomique Inst Nat Rech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Univ Paris Curie, Agronomique Inst Nat Rech filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE498683T1 publication Critical patent/ATE498683T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/5759Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT05809259T 2004-11-26 2005-11-24 Leptin antagonisten ATE498683T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/996,607 US7307142B2 (en) 2004-11-26 2004-11-26 Leptin antagonists
PCT/IL2005/001250 WO2006056987A2 (en) 2004-11-26 2005-11-24 Leptin antagonists

Publications (1)

Publication Number Publication Date
ATE498683T1 true ATE498683T1 (de) 2011-03-15

Family

ID=36204374

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05809259T ATE498683T1 (de) 2004-11-26 2005-11-24 Leptin antagonisten

Country Status (8)

Country Link
US (1) US7307142B2 (de)
EP (1) EP1814986B1 (de)
JP (1) JP5113526B2 (de)
CN (1) CN101189335B (de)
AT (1) ATE498683T1 (de)
DE (1) DE602005026432D1 (de)
ES (1) ES2363011T3 (de)
WO (1) WO2006056987A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
WO2009143380A2 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2010054017A1 (en) * 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
WO2010117785A1 (en) * 2009-03-31 2010-10-14 Temple University - Of The Commonwealth System Of Higher Education Leptin antagonist and methods of use
MX2012012229A (es) * 2010-04-22 2013-03-05 Yissum Res Dev Co Leptinas de alta afinidad y antagonistas de leptina.
WO2014024189A1 (en) * 2012-08-06 2014-02-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pegylated high affinity leptins with increased biological activity
IT1423968B1 (de) * 2014-04-28 2016-08-26
CA2977607A1 (en) * 2015-02-26 2016-09-01 Jacob Schneiderman Methods and compositions relating to leptin antagonists
US10926006B2 (en) 2015-02-26 2021-02-23 Remodeless Cv Ltd Drug eluting stent
US11123461B2 (en) 2015-02-26 2021-09-21 Remodeless Cv Ltd Treatment of ischemia and reperfusion using leptin antagonist
CN104829707B (zh) 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829708B (zh) * 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
US10550192B2 (en) * 2016-11-08 2020-02-04 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
EP3898672A1 (de) 2018-12-18 2021-10-27 Regeneron Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur erhöhung des körpergewichts und der magermuskelmasse unter verwendung von antagonisten gegen leptinrezeptor, gdf8 und activin a
WO2024050285A2 (en) * 2022-08-31 2024-03-07 The Board Of Trustees Of The Leland Stanford Junior University Leptin analogs for treating obesity and weight management

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
US20020160935A1 (en) 2000-03-24 2002-10-31 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
HUP9904023A3 (en) 1996-09-20 2002-01-28 Hoechst Ag Use of leptin antagonists for treating insulin resistance in type ii diabetes
CA2437265A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified leptin with reduced immunogenicity

Also Published As

Publication number Publication date
EP1814986A2 (de) 2007-08-08
WO2006056987A3 (en) 2006-08-24
US20060154859A1 (en) 2006-07-13
JP5113526B2 (ja) 2013-01-09
WO2006056987A2 (en) 2006-06-01
US7307142B2 (en) 2007-12-11
CN101189335A (zh) 2008-05-28
EP1814986B1 (de) 2011-02-16
JP2008521795A (ja) 2008-06-26
ES2363011T3 (es) 2011-07-18
CN101189335B (zh) 2012-01-11
DE602005026432D1 (de) 2011-03-31

Similar Documents

Publication Publication Date Title
ATE498683T1 (de) Leptin antagonisten
NL301089I2 (nl) imlifidase
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
TW200745163A (en) Peptides that block the binding of IgG to FcRn
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
WO2006017538A3 (en) Hk1-binding proteins
DK2035447T3 (da) Polypeptid
LU91989I2 (fr) Bydureon
EA200700136A1 (ru) Анти-cd154-антитела
MX2008011874A (es) Composiciones estabilizadas de polipeptidos.
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
ATE428727T1 (de) Neue, an den erythropoietinrezeptor bindende peptide
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
EP1768698A4 (de) Immunogene zusammensetzungen mit hmgb1-polypeptiden
SMAP200800060A (it) Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptpbeta) e loro usi
EA201100072A1 (ru) Новые композиции и способы
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
WO2006138343A3 (en) Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
ATE514714T1 (de) Hutnfr1-selektive antagonisten
MA56397A (fr) Protéines de liaison à l'il1rap
EA201100071A1 (ru) Новые композиции и способы
WO2008086035A3 (en) Split mutant hydrolase fusion reporter and uses thereof
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties